TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05688436
Drug: Ponesimod
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05688436
Drug: Siponimod
Normalized name: SIPONIMOD
DrugBank: Siponimod (DB12371)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as specified in the treatment arm.
Study: NCT06008522
Drug: Bevacizumab-800CW
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imaging of fluorescently labeled Bevacizumab-800CW using OCT.
Study: NCT06586684
Drug: Inclisiran
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with carotid plaques undergoing treatment with inclisiran
Study: NCT06679374
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.
Study: NCT05220020
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental group(Synchronous treatment group): the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.Control group:(Sequential treatment group)patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
Study: NCT06789614
Drug: intravenous CYCLIZINE ,Metaclopromide
DrugBank: Cyclizine (DB01176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: US giuded measure of GRV in bariatrics surgery upon recieving drugs of study
Study: NCT05994690
Drug: Investigational Intervention Rc
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 consolidation courses (HAM + FLA)
Study: NCT05994690
Drug: Standard Intervention Ri
Normalized name: RI 624
DrugBank: RI 624 (DB05892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No addition of GO to first induction course
Study: NCT05751850
Drug: nab-paclitaxel; gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nab-paclitaxel in combination with gemcitabine
Study: NCT03740516
Drug: CC-10004
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-10004 will be administered orally
Study: NCT05757570
Drug: povetacicept
Normalized name: Povetacicept
DrugBank: Povetacicept (DB18996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection every 4 weeks
Study: NCT04288713
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A distal complement inhibitor.
Study: NCT04550234
Drug: Verinurad prolonged release HPMC capsule
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive oral dose of verinurad HPMC capsule.
Study: NCT04550234
Drug: Allopurinol Tablet
Normalized name: Allopurinol Tablets
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized subjects will receive oral dose of allopurinol tablet.
Study: NCT04550234
Drug: Verinurad/Allopurinol FDC Capsule
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.
Study: NCT04550234
Drug: Verinurad prolonged release gelatin Capsule
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive oral dose of Verinurad gelatin capsule.
Study: NCT04200729
Drug: Irrigation with PVI
Normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention will be irrigation with PVI, diluted to a concentration of 1% (containing 0.1% active iodine). After removal of the appendix from the patient's abdomen and attainment of hemostasis,10 mL/kg of 1% PVI solution will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned.
Study: NCT05546515
Drug: Suvorexant (dual orexin receptor antagonist)
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be prescribed up to 30 days of SUVO.
Study: NCT05607342
Drug: Osanetant
Normalized name: Osanetant
DrugBank: Osanetant (DB04872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the effect of Osanetant on the testosterone levels.
Study: NCT06789900
Drug: Everolimus (Afinitor®)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral dose of everolimus 5 mg once a week for 24 weeks
Study: NCT06799494
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 1% will be injected intradermally and subcutaneously into the margin of the lymph node to be sampled to numb the area. To confer local anesthesia, 1-2% will be injected into the tissue surrounding the area where the bone marrow will be removed.
Study: NCT06799494
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam, an FDA-approved benzodiazepine, will be administered as an anxiolytic before the bone marrow aspirate procedure per the clinician who will perform the procedure. If needed, lorazepam will be administered sublingually per manufacturer dosing recommendations.
Study: NCT06300658
Drug: Stellate ganglion block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive preemptive stellate ganglion block (SGB) just before spinal anesthesia.
Study: NCT05304468
Drug: cisplatin concurrent chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)
Study: NCT06598917
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Treatment schedule At 4 to 8 weeks after chemotherapy and radiotherapy ended, maintenance S-1 was administered for up to 12 cycles. A cycle was 3 weeks, with S-1 administrated on days 1 to 14 in each cycle.~The initial dose of S-1 was determined according to the body surface area (BSA): 40 mg twice a day for BSA \&lt; 1.25 m2; 50 mg twice a day for 1.25 m2⩽ BSA \&lt; 1.5 m2; and 60 mg twice a day for BSA ⩾1.5 m2.~Maintenance chemotherapy with S1 was administered for 12 cycles or terminated earlier if there was disease progression, intolerable toxicity, or at the patient's request.
Study: NCT06600841
Drug: Immunotherapy（Adebrelimab）
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab plus non-platinum chemotherapy（Liposomal doxorubicin/Gemcitabine/ or nab-paclitaxel）and fluzoparib induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.
Study: NCT06600841
Drug: immunotherapy（Adebrelimab）
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-L1
Study: NCT06093126
Drug: Lemborexant 5 MG
Normalized name: lemborexant 5 MG
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The participant will receive 8 weeks of treatment Week 1 = placebo Week 2 = lemborexant 5mg Week 3 = lemborexant 10 mg Week 4 = placebo Week 5 = lemborexant 10 mg Week 6 = placebo Week 7 = placebo Week 8 = lemborexant 10 mg
Study: NCT05330130
Drug: Follitropin beta injection 150 IU
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.
Study: NCT05330130
Drug: Follitropin beta injection 300 IU
Normalized name: follitropin beta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.
Study: NCT06785337
Drug: Inhaled nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitroglycerin
Study: NCT05393791
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Use of abiraterone or enzalutamide
Study: NCT05393791
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use of abiraterone or enzalutamide
Study: NCT06145321
Drug: G-CSF administration (bolus injection versus intravenous infusion)
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
Study: NCT06614881
Drug: Dexmedetomidine Injection [Precedex]
Normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Precedex, 100 µg/ml) was provided as an intravenous (IV) loading dose of 1 µg/kg over 10-min
Study: NCT06614881
Drug: Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Normalized name: dexmedetomidine in 0.9 % NaCl 1,000 mcg/250 mL (4 mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine infusions were prepared to provide 0.5 µg/kg/h
Study: NCT06614881
Drug: Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Normalized name: dexmedetomidine in 0.9 % NaCl 1,000 mcg/250 mL (4 mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine infusions were prepared to provide 0.7 µg/kg/h
Study: NCT06614881
Drug: Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Normalized name: dexmedetomidine in 0.9 % NaCl 1,000 mcg/250 mL (4 mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine infusions were prepared to provide 1.1 µg/kg/h
Study: NCT06538480
Drug: PRGN-2012
Normalized name: PRGN-2012
DrugBank: PRGN-2012 (DB18342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRGN-2012 will be administered as 4 subcutaneous administrations over a 12-week interval.
Study: NCT06766019
Drug: Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. adebrelimab 1200mg, i.v. D1, q28d~2. irinotecan liposomal (II) 60mg/m\^2, i.v. D1, Q2W~3. oxaliplatin 85mg/m\^2, i.v. D1, Q2W~4. 5-FU/LV 2400mg/400mg/m\^2, i.v. D1, Q2W 4-week cycles, 6 cycles
Study: NCT06765330
Drug: CHX disinfection
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each CHX cavity will be treated with disinfectant with a disposable micro brush tip and left undisturbed for 20 seconds. They will then be air-dried for 10 seconds and restore the tooth.
Study: NCT04409639
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
Study: NCT05587036
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin oral tablet, 550 mg, twice daily, two-weeks
Study: NCT06765590
Drug: R, 260 mg/m2, paclitaxel for injection (albumin bound).
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: R, 260 mg/m2, paclitaxel for injection (albumin bound).
Study: NCT05845424
Drug: High intensity statin plus ezetimibe therapy
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20 mg + Ezetimibe 10 mg
Study: NCT05611801
Drug: marstacimab
Normalized name: Marstacimab
DrugBank: Marstacimab (DB17725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: marstacimab
Study: NCT05680805
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1500 mg/day in 3 divided dose for 24 weeks
Study: NCT06302348
Drug: Sepiapterin
Normalized name: Sepiapterin
DrugBank: Sepiapterin (DB16326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.
Study: NCT05491811
Drug: Ensartinib
Normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study: NCT05491811
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study: NCT05744401
Drug: AL002
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered via intravenous (IV) infusion
Study: NCT05370495
Drug: SY-201 Ophthalmic Solution Vehicle
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SY-201 Ophthalmic Solution Vehicle
Study: NCT05555706
Drug: B013+Nab-Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle.
Study: NCT05453552
Drug: Granulocyte Colony-Stimulating Factor(G-CSF)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
Study: NCT06009653
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week.
Study: NCT05453552
Drug: Decitabine (DAC)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.
Study: NCT05453552
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
Study: NCT05453552
Drug: Fludarabine (FLU)
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
Study: NCT05453552
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
Study: NCT06400160
Drug: TB511
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TB511 is a peptide drug conjugate (PDC) which composed of TAMpep826 peptide. TB511 is a white amorphous powder used for subcutaneous injections. TB511 is a peptide drug conjugate that combines a transporter peptide with a specific targeting of M2 macrophages and an apoptosis-inducing peptide (dKLA). As a transporter, the M2 binding peptide acts as a drug conjugate, explicitly binding to M2 macrophages and inducing cell penetration. In the cells, the dKLA component of TB511 binds to the mitochondrial membrane, destroys the mitochondrial membrane, and induces apoptosis by causing cytochrome release, leading to the destruction of the mitochondria and subsequent death of M2 macrophages.
Study: NCT06400160
Drug: Keytruda
Normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.
Study: NCT06541574
Drug: Sham Injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Injection
Study: NCT06594172
Drug: Memantine Oral Tablet
Normalized name: memantine Oral Tablet
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Memantine Tablets (10mg/tablet):~Week 1: 5mg in the morning. Week 2: 5mg twice daily. Week 3: 10mg in the morning, 5mg in the evening. Weeks 4-24: 10mg twice daily.
Study: NCT06594172
Drug: Pioglitazone 15mg
Normalized name: METFORMIN 500MG/PIOGLITAZONE 15MG TAB
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous oral administration of Pioglitazone Tablets (15mg/tablet):~Weeks 1-24: 30mg once daily.
Study: NCT06592170
Drug: Linperlisib combination with obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Safe import period: Linperlisib: 80 mg, oral (pre - and post meal), QD; obinutuzumab: 1000 mg, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there is one cycle in total.~Extended treatment period: Combination induction: Linperlisib: RP2D, oral (pre - and post meal), QD; obinutuzumab: 1000 mg/time, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there are 2 cycles in total. Afterwards, single drug maintenance: Linperlisib: RP2D, oral (before and after meals), QD; every 28 days per cycle.
Study: NCT04606914
Drug: mirvetuximab soravtansine (MIRV; IMGN853)
Normalized name: mirvetuximab soravtansine
DrugBank: Mirvetuximab soravtansine (DB12489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirvetuximab soravtansine (also known as IMGN853 and MIRV) is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridin-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB) linker. FRα is a glycosyl-phosphatidylinositol (GPI)-linked protein, which shows limited normal tissue expression and high expression on the surface of solid tumors, particularly epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (referenced herein collectively as EOC), endometrial cancer, non-small cell lung cancer (NSCLC), and renal cell cancer.
Study: NCT06587698
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg QD for 3 month
Study: NCT06587698
Drug: Sitagliptin+BeiDouGen
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month
Study: NCT04883281
Drug: cisplatin, cetuximab, or carboplatin-paclitaxel
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
Study: NCT05279755
Drug: prosetin
Normalized name: Prosetin
DrugBank: Prosetin (DB18649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT05485896
Drug: Pembrolizumab plus Lenvatinib
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles in the preoperation. Additional 17 cycles of Pembrolizumab were needed for patients with high risk of recurrence (tumor stage 2 with nuclear grade IV or sarcomatoid differentiation, tumor stage 3 or higher, regional lymph-node metastasis, or stage M1 with no evidence of disease residual).
Study: NCT06547619
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
Study: NCT04910776
Drug: avalglucosidase alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sterile lyophilized powder intravenous (IV) infusion
Study: NCT06272487
Drug: Zilebesiran
Normalized name: Zilebesiran
DrugBank: Zilebesiran (DB18929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilebesiran administered by subcutaneous (SC) injection